Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
ORGANIZATION
NEDO, NCC, Toray to Jointly Develop Simple Test Systems for Cancers and Dementia
The New Energy and Industrial Technology Development Organization (NEDO), the National Cancer Center (NCC), Toray Industries, and other companies and organizations announced on August 18 that they will begin jointly developing diagnostic devices and test systems that can be easily…
To read the full story
ORGANIZATION
- JPMA Launches Task Force on AI and Open Innovation Challenges: IP Chief
September 18, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
- JPMA Names Ex-MHLW Pharma Official Yoshida as Senior Managing Director
September 12, 2025
- JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…